Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Arnold Gelb"'
Autor:
Christina Amidei, Daniel J. Brat, Rimas V. Lukas, Alexander Z. Feldman, Jill Buck, Karan Dixit, Craig Horbinski, Matthew C. Tate, Sean Sachdev, Lawrence J. Jennings, Nathan Demars, Matthew McCord, Arnold Gelb
Publikováno v:
Neuro-oncology Advances
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff5e155eddca051593dcd98681db6ea0
http://europepmc.org/articles/PMC8262637
http://europepmc.org/articles/PMC8262637
Autor:
Jill Buck, Yunxia Wang, Nira Hadar, Laurence J.N. Cooper, Nathan Demars, John Miao, John Loewy, John S. Yu, Nancy Ann Oberheim Bush, Rimas V. Lukas, Joseph Landolfi, Arnold Gelb, Robert Cavaliere, Sylvia Kurz, E. Antonio Chiocca
Publikováno v:
Neuro Oncol
Ad-RTS-hIL-12 (Ad) is a gene therapy candidate for intratumoral (IT) delivery that conditionally expresses IL-12 (IL-12) under the transcriptional control of orally administered veledimex (V) acting via the RheoSwitch Therapeutic Systemâ gene switch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c81a9468f41bd3331cc06fa6cc0f2f
https://europepmc.org/articles/PMC7650356/
https://europepmc.org/articles/PMC7650356/
Autor:
Nathan Demars, Yunxia Wang, Laurence J.N. Cooper, Amy Smith, John Miao, Ennio Antonio Chiocca, Arnold Gelb, Jill Buck, Sylvia Kurz, Rimas V. Lukas, John S. Yu, John Zhou, Ganesh Rao, Joseph Landolfi
Publikováno v:
Neuro Oncol
Ad-RTS-hIL-12 (Ad) is a novel gene therapy, conditionally expressing IL-12 via the RheoSwitch Therapeutic System® (RTS®) gene switch under control of an oral activator ligand, veledimex (V). We previously reported results from 51 subjects (NCT02026
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ceb0131cf8d19db1b45fb83fa8e382e
https://europepmc.org/articles/PMC6847372/
https://europepmc.org/articles/PMC6847372/
Autor:
Laurence J.N. Cooper, Arnold Gelb, Francois Lebel, Hiroshi Nakashima, John A. Barrett, Isaac H. Solomon, Jill Buck, Jethro Hu, Patrick Y. Wen, Jeremy Rudnick, Priya Kumthekar, Rimas V. Lukas, John Zhou, Bakhtiar Yamini, Daniel Triggs, David A. Reardon, Brittany M. Stopa, Nathan Demars, Ajay Naik, Keith L. Ligon, John S. Yu, E. Antonio Chiocca
Publikováno v:
Sci Transl Med
Human interleukin-12 (hIL-12) is a cytokine with anticancer activity, but its systemic application is limited by toxic inflammatory responses. We assessed the safety and biological effects of an hIL-12 gene, transcriptionally regulated by an oral act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33462db1bc2ce9b1ecc0e48df69dff31
https://pubmed.ncbi.nlm.nih.gov/31413142
https://pubmed.ncbi.nlm.nih.gov/31413142
Autor:
Laurence J.N. Cooper, Erin Walsh, John Miao, Arnold Gelb, Sabine Mueller, Rudy Allen, Amanda Saratsis, Nira Hadar, Stewart Goldman, Taylor Estupinan, Jill Buck, Nathan Demars, Susan N. Chi
Publikováno v:
Neuro Oncol
DIPG, which is the leading cause of pediatric brain cancer death with no effective treatment, has neither a highly immunosuppressive nor inflammatory tumor microenvironment (TME). Therefore, eliciting a pro-inflammatory TME may provide therapeutic be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b922cb7fbd95e5af309ec3ff329fb1d3
https://doi.org/10.1093/neuonc/noaa215.161
https://doi.org/10.1093/neuonc/noaa215.161
Autor:
Yunxia Wang, Taylor Estupinan, Rimas V. Lukas, Christina Amidei, John Loewy, Nathan Demars, Jill Buck, Arnold Gelb, Ganesh Rao, Nira Hadar, E. Antonio Chiocca, Laurence J.N. Cooper, John Miao, Clark C. Chen
Publikováno v:
Neuro Oncol
A published clinical trial of veledimex (V)-regulatable interleukin-12 (IL-12) gene therapy (“Controlled IL-12”) under the control of a transcriptional switch (RheoSwitch Therapeutic Systemâ, RTSâ) as monotherapy in recurrent glioblastoma (rGBM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a6ad45959813348722590797be296b9
https://doi.org/10.1093/neuonc/noaa215.139
https://doi.org/10.1093/neuonc/noaa215.139
Autor:
John Loewy, Christina Amidei, Jill Buck, E. Antonio Chiocca, John S. Yu, Yunxia Wang, Nira Hadar, Arnold Gelb, Nathan Demars, Bakhtiar Yamini, Nancy Ann Oberheim Bush, Rimas V. Lukas, Taylor Estupinan, Laurence J.N. Cooper, John Miao
Publikováno v:
Journal of Clinical Oncology. 38:3040-3040
3040 Background: Interleukin-12 (IL-12), a master regulator of the immune system, results in anti-tumor responses in preclinical models, but safe use requires tightly controlled production. This phase 1 trial (NCT02026271) is the first to evaluate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f82b7c1eb8f55e95c81e1f653596eff5
https://doi.org/10.1200/jco.2020.38.15_suppl.3040
https://doi.org/10.1200/jco.2020.38.15_suppl.3040
Autor:
Nira Hadar, Arnold Gelb, Laurence J.N. Cooper, John Miao, E. Antonio Chiocca, John Loewy, Rimas V. Lukas, Christina Amidei, Taylor Estupinan, Jill Buck, Yunxia Wang, Nathan Demars, Ganesh Rao, Clark C. Chen
Publikováno v:
Journal of Clinical Oncology. 38:2510-2510
2510 Background: Monotherapy with intratumoral Ad-RTS-hIL-12 (Ad), a gene therapeutic conditionally expressing IL-12 under the transcriptional control of oral veledimex (“Controlled IL-12”), was shown in a phase 1 study (NCT02026271) to elicit a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf9416ac8d75cf9fc62599ba33f9a4a7
https://doi.org/10.1200/jco.2020.38.15_suppl.2510
https://doi.org/10.1200/jco.2020.38.15_suppl.2510
Autor:
Ganesh Rao, Sylvia Kurz, Yunxia Wang, Christina Amidei, Taylor Estupinan, Nathan Demars, Joseph Landolfi, Rimas V. Lukas, John S. Yu, Laurence J.N. Cooper, John Miao, Arnold Gelb, Jill Buck, John Loewy, Nira Hadar
Publikováno v:
Journal of Clinical Oncology. 38:2564-2564
2564 Background: Interleukin-12 (IL-12) results in anti-tumor responses in preclinical models but requires tightly controlled production to achieve safety and elicit immune system activation to realize efficacy. A phase 1 “main study” (NCT0202627
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7bcce6e93674a66f16531f20754da43
https://doi.org/10.1200/jco.2020.38.15_suppl.2564
https://doi.org/10.1200/jco.2020.38.15_suppl.2564
Autor:
Francois Lebel, John S. Yu, John A. Barrett, Laurence J.N. Cooper, Arnold Gelb, E. Antonio Chiocca, Rimas V. Lukas, Nancy Ann Oberheim Bush, Yunxia Wang, Jill Buck, Nathan Demars
Ad-RTS-hIL-12 (Ad) is a novel gene therapy expressing IL-12 via the RheoSwitch Therapeutic System(®) gene switch under control of an oral activator ligand, veledimex (V). We previously reported on an open label Phase I trial describing biological ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecbc80d5a809c1b202caa5e12d896232
https://europepmc.org/articles/PMC6216124/
https://europepmc.org/articles/PMC6216124/